0 Valutazioni
ID

46172

Descrizione

Principal Investigator: Howard McLeod, Moffitt Cancer Center, Tampa, FL, USA MeSH: Prostatic Neoplasms,Neutropenia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001002 The Cancer and Leukemia Group B (CALGB) 90401 trial compared docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer. A genome-wide association study using clinical outcomes and toxicities was conducted on the basis of data from CALGB patients who provided consent for pharmacogenomic studies and usable DNA

collegamento

dbGaP study=phs001002

Keywords

versioni (2)
  1. 09/11/23 09/11/23 - Simon Heim
  2. 29/01/25 29/01/25 - Akane Nishihara
Titolare del copyright

Howard McLeod, Moffitt Cancer Center, Tampa, FL, USA

Caricato su

29 gennaio 2025

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

  • i più nuovi
  • i più vecchi
  • Popolare
  • i più nuovi
    • i più nuovi
    • i più vecchi
    • Popolare

    Non ci sono commenti

    Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

    dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS

    Inglese

    Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.

    5 moduli  
    1. StudyEvent: dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
      1. Eligibility Criteria
      2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
      3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
      4. Subject ID, neuropathy, neutropenia, genetic European status, age, sex, hemoglobin, palliative radiation, specimen(s) limitations, blood specimen, ethnicity, race, medical history of participant smoking and venous and arterial thromboembolism, arterial and or venous thromboembolism, BMI, diabetes, gastrointestinal tract, hemorrhage, Khorana risk status, anti-platelet or anti-coagulant use, and treatment arm assignment of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
      5. Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    pht005043
    Descrizione

    pht005043

    Alias
    UMLS CUI [1,1]
    C3846158 (Other Coding)
    LOINC
    LA4728-7
    Subject ID
    Descrizione

    SUBJECT_ID

    Tipo di dati

    string

    Alias
    UMLS CUI [1,1]
    C2348585 (Clinical Trial Subject Unique Identifier)
    Sample ID
    Descrizione

    SAMPLE_ID

    Tipo di dati

    string

    Alias
    UMLS CUI [1,1]
    C1299222 (Sample identification number)
    SNOMED
    372274003
    Source repository where samples originate
    Descrizione

    SAMPLE_SOURCE

    Tipo di dati

    string

    Alias
    UMLS CUI [1,1]
    C3847505 (Repository)
    LOINC
    LP182360-0
    UMLS CUI [1,2]
    C0449416 (Source)
    SNOMED
    260753009
    LOINC
    LP21212-3
    UMLS CUI [1,3]
    C2347026 (Biospecimen)
    Sample ID used in the Source Repository
    Descrizione

    SOURCE_SAMPLE_ID

    Tipo di dati

    string

    Alias
    UMLS CUI [1,1]
    C1299222 (Sample identification number)
    SNOMED
    372274003
    UMLS CUI [1,2]
    C3847505 (Repository)
    LOINC
    LP182360-0
    UMLS CUI [1,3]
    C0449416 (Source)
    SNOMED
    260753009
    LOINC
    LP21212-3
    Sample Use
    Descrizione

    SAMPLE_USE

    Tipo di dati

    text

    Alias
    UMLS CUI [1,1]
    C2347026 (Biospecimen)
    UMLS CUI [1,2]
    C1524063 (Use of)
    SNOMED
    260676000
    Ritorna all'inizio della pagina

    Similar models

    Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.

    5 moduli
    1. StudyEvent: dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
      1. Eligibility Criteria
      2. Subject ID, consent group, subject source, source subject ID, and affection status of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
      3. Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
      4. Subject ID, neuropathy, neutropenia, genetic European status, age, sex, hemoglobin, palliative radiation, specimen(s) limitations, blood specimen, ethnicity, race, medical history of participant smoking and venous and arterial thromboembolism, arterial and or venous thromboembolism, BMI, diabetes, gastrointestinal tract, hemorrhage, Khorana risk status, anti-platelet or anti-coagulant use, and treatment arm assignment of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
      5. Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
    Name
    genere
    Description | Question | Decode (Coded Value)
    Tipo di dati
    Alias
    Item Group
    pht005043
    C3846158 (UMLS CUI [1,1])
    SUBJECT_ID
    Item
    Subject ID
    string
    C2348585 (UMLS CUI [1,1])
    SAMPLE_ID
    Item
    Sample ID
    string
    C1299222 (UMLS CUI [1,1])
    SAMPLE_SOURCE
    Item
    Source repository where samples originate
    string
    C3847505 (UMLS CUI [1,1])
    C0449416 (UMLS CUI [1,2])
    C2347026 (UMLS CUI [1,3])
    SOURCE_SAMPLE_ID
    Item
    Sample ID used in the Source Repository
    string
    C1299222 (UMLS CUI [1,1])
    C3847505 (UMLS CUI [1,2])
    C0449416 (UMLS CUI [1,3])
    Item
    Sample Use
    text
    C2347026 (UMLS CUI [1,1])
    C1524063 (UMLS CUI [1,2])
    SAMPLE_USE
    Code List
    Sample Use
    CL Item
    SNP genotypes obtained using standard or custom microarrays (Array_SNP)
    C2347026 (UMLS CUI [1,1])
    C0042153 (UMLS CUI [1,2])
    C0752046 (UMLS CUI [1,3])
    C1449575 (UMLS CUI [1,4])
    Ritorna all'inizio della pagina 

    Aiuto

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial